Prof Michail Ignatiadis talks to ecancer about neoadjuvant therapy and pathological complete response (PCR) at IMPAKT 2012 in Brussels, May 2012.

The study conducted looks at whether or not neoadjuvant therapy should be used in order to reach pathological complete response. Results have shown that this can occur after commonly used therapies.

Data shows that patients with HER2 amplified and triple negative tumours have excellent response when receiving chemotherapy before surgery. After treatment, biopsies can be used to determine tumour type and its sensitivity to chemotherapy for future record. The most important finding in the study was that the immune response module had a signficantly higher probability of complete pathological response.

Filming Supported by Amgen